Product Description: Carbamazepine (Standard) is the analytical standard of Carbamazepine. This product is intended for research and analytical applications. Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker with an IC50 of 131 μM. Carbamazepine blocks voltage gated Na+, Ca2+, and K+ channels, and is also a HDAC inhibitor (IC50: 2 μM). Carbamazepine is an anticonvulsant and can be used for research of epilepsy and neuropathic pain[1][2][3].
Formula: N/A
References: [1]Willow, M. and W.A. Catterall, Inhibition of binding of [3H]batrachotoxinin A 20-alpha-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol, 1982. 22(3): p. 627-35./[2]Okada, M., et al., Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus. Epilepsy Res, 1997. 28(2): p. 143-53./[3]Beutler AS, et al. Carbamazepine is an inhibitor of histone deacetylases. Life Sci. 2005 May 13;76(26):3107-15./[4]Turpin E, et al. Carbamazepine directly inhibits adipocyte differentiation through activation of the ERK 1/2 pathway. Br J Pharmacol. 2013 Jan;168(1):139-50./[5]Wang CH, et al. Carbamazepine attenuates inducible nitric oxide synthase expression through Akt inhibition in activated microglial cells. Pharm Biol. 2014 Nov;52(11):1451-9. /[6]Kawaguchi T, et al. Carbamazepine promotes liver regeneration and survival in mice. J Hepatol. 2013 Dec;59(6):1239-45./[7]Kara NZ, et al. Chronic oral carbamazepine treatment elicits mood-stabilising effects in mice. Acta Neuropsychiatr. 2014 Feb;26(1):29-34.
CAS Number: 298-46-4
Molecular Weight: N/A
Research Area: Neurological Disease; Cancer
Target: Autophagy;Calcium Channel;HDAC;Mitophagy;Potassium Channel;Sodium Channel
English
Deutsch
